Kymera Therapeutics, Inc. (KYMR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $73.57: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 3.67; Below-average business quality.
Kymera Therapeutics is a clinical-stage biopharmaceutical company using targeted protein degradation (TPD) to develop oral medicines for immune-inflammatory diseases. Its lead programs target STAT6 (KT-621, Phase 2b in atopic dermatitis and asthma), IRF5 (KT-579, Phase 1), and... Read more
Sell if holding. Engine safety override at $73.57: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 3.67; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 62d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Kymera Therapeutics, Inc.
Latest news
- NEWS Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, — benzinga Jun 9, 2026 positive
- NEWS Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modif — benzinga Jun 8, 2026 positive
- NEWS Kymera Therapeutics Announces Presentations On Results From KT-621 Clinical Trial At Annual Meetings May 13-16 — benzinga May 15, 2026 positive
- NEWS Canaccord Genuity Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $106 — benzinga May 6, 2026 positive
- NEWS Kymera Therapeutics Presented New Preclinical Data For KT-579 Demonstrating Disease-modifying Activity In An Inflammator — benzinga May 5, 2026 positive
Generated 2026-06-09T22:21:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-26Item 1.01LOWKymera entered at-the-market Sales Agreement with TD Cowen for up to $500M common stock offering. TD Cowen receives up to 3.0% commission. Company not obligated to sell; program active on Nasdaq.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·3 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $73.57: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 3.67; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $68.19. Score 5.6/10, moderate confidence.
Take-profit target: $106.45 (+45.2% upside). Prior stop was $68.19. Stop-loss: $68.19.
Quality below floor (1.6 < 4.0).
Kymera Therapeutics, Inc. trades at a P/E of N/A (forward -16.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
30 analysts cover KYMR with a consensus score of 4.3/5. Average price target: $118.
What does Kymera Therapeutics, Inc. do?Kymera Therapeutics is a clinical-stage biopharmaceutical company using targeted protein degradation (TPD) to develop...
Kymera Therapeutics is a clinical-stage biopharmaceutical company using targeted protein degradation (TPD) to develop oral medicines for immune-inflammatory diseases. Its lead programs target STAT6 (KT-621, Phase 2b in atopic dermatitis and asthma), IRF5 (KT-579, Phase 1), and IRAK4 (KT-485 via Sanofi collaboration). The company has no product revenue and had $1.6B cash as of Dec 31, 2025.